Neuronal ceroid lipofuscinoses (NCLs) are a heterogeneous group of lysosomal storage disorders. NCLs include the rare autosomal recessive neurodegenerative disorder neuronal ceroid lipofuscinosis type 2 (CLN2) disease, caused by mutations in the tripeptidyl peptidase 1 (TPP1)/CLN2 gene and the resulting TPP1 enzyme deficiency.
Introduction
Neuronal ceroid lipofuscinosis type 2 (CLN2) disease (OMIM 204500) is a rare autosomal recessive lysosomal storage disorder that results from deficient activity of the lysosomal exopeptidase tripeptidyl peptidase 1 (TPP1) enzyme (EC 3.4.14.9) caused by mutations in the TPP1/CLN2 gene (GenBank accession no. NM_000391.3) [1] . As in other neuronal ceroid lipofuscinosis (NCL) disorders (Table 1) , CLN2 disease leads to intralysosomal accumulation of autofluorescent storage materials and neuronal loss.
The in vivo substrate(s) of TPP1 are not known, and the molecular pathology of TPP1 enzyme deficiency is poorly understood [2] . CLN2 disease incidence estimates range from 0.22 to 9.0 per 100,000 live births, but it is possible that it is under-recognized [2] [3] [4] .
The classic phenotype of CLN2 disease is the most common form of NCL with lateinfantile onset (roughly defined as ages 2-4 years) and generally manifests with newonset seizures and/or ataxia, typically in combination with a history of early language delay [5] . Classic phenotype disease progression is rapid, leading to the loss of acquired developmental milestones, new or worsening ataxia, movement disorders (myoclonus, dystonia, and chorea), progressive dementia, and eventual loss of vision [3, [5] [6] [7] [8] [9] . A majority of those diagnosed with CLN2 disease die prematurely after becoming bedridden and blind. The more rare atypical phenotypes are characterized by varied ages of initial presentation and/or longer life expectancy [5, [10] [11] [12] . An example of atypical CLN2 disease is spinocerebellar ataxia autosomal recessive 7 (SCAR7; OMIM 609270), which was initially described as a distinct disorder but is in fact caused by partially A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 6 deficient TPP1 enzyme activity; individuals with SCAR7 develop ataxia and cerebellar atrophy but do not develop seizures or loss of vision [12] .
In May 2015, 13 international laboratory and clinical NCL experts met both to develop a CLN2 disease-specific diagnostic algorithm ( Figure 1 ) and to define the gold standard diagnostic laboratory tests to support an early and accurate diagnosis of CLN2 disease.
Clinical suspicion and paths to diagnosis of CLN2 disease
Developing a specific suspicion of CLN2 disease through differential diagnosis is often a protracted process, due in part to lack of pathognomonic signs at onset. Based on the expert meeting discussions, three general paths lead to a laboratory diagnosis of CLN2 disease, depending on degree of CLN2 disease suspicion ( Figure 1 ).
High suspicion of CLN2 disease
CLN2 disease is rarely suspected or diagnosed at initial presentation to the clinic unless there is already a known, affected family member. Because CLN2 disease is one of the most common of NCL disorders [13] , children who ultimately present to an NCL specialist with ataxia, worsening unprovoked seizures, history of language delay and/or are at a developmental stand-still will follow a clear, direct, path specific for a high suspicion of classic CLN2 disease (Figure 1 , center) [5] . Typically, diagnosis only occurs after a series of misdiagnoses, as the early disease course is clinically similar to many other seizure and/or metabolic disorders.
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An EEG is often the first clinical test performed irrespective of the level of specific clinical suspicion ( Figure 1 ). In cases of CLN2 disease, electroencephalograms (EEGs) may detect irregular activity, a slowing of background activity, and epileptiform abnormalities in posterior regions. Visual evoked potentials reveal an increase of latency;
optical coherence tomography may detect ocular abnormalities; and electroretinograms may be diminished [3, 5, 8, 14, 15] . Ocular abnormalities and vision defects can be subtle initially but increase in prominence with disease progression [5, 8, 15] .
Findings of brain imaging techniques (such as magnetic resonance imaging) include progressive cerebellar and cerebral atrophy, reductions in grey matter volume, and periventricular white matter hyperintensities [8, [16] [17] [18] [19] . It is important to recognize that although CLN2 is a grey matter disease, periventricular white matter hyperintensities may be seen and should not deviate the diagnosis path towards a leukodystrophy. These findings may provide clues for diagnosis.
EEG with intermittent photic stimulation (IPS) performed at a frequency of 1 to 2 Hz is a particularly informative test. In many EEGs of patients ultimately diagnosed with CLN2 disease a characteristic flash-per-flash response has been reported at low frequency of stimulation. A classical epileptiform photoparoxysmal response is usually evident at higher frequencies of stimulation [3, 5, [20] [21] [22] . Although IPS is often part of routine assessment performed in response to new-onset seizures, if performed only at frequencies of > 2 Hz, the characteristic response (at 1-2 Hz) that is present in many individuals with CLN2 disease will be missed. Lack of a characteristic response cannot rule out CLN2 disease, however.
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High suspicion of an NCL disorder
More commonly, a history of ataxia, worsening unprovoked seizures and presence of early language delay may not specifically be recognized as CLN2 disease but may be generally suggestive of an NCL disorder upon presentation to a metabolic specialist/ geneticist, an NCL specialist, or a pediatric neurologist with experience diagnosing NCL disorders. Upon a general suspicion of an NCL disorder (Figure 1, right 
High suspicion of genetic basis for epilepsy/neurological symptoms
Most commonly, initial presentation of ataxia and/or unprovoked seizures and a history of a language delay to a pediatrician or even to a pediatric neurologist, results in no specific suspicion of CLN2 disease or NCL. Seizures are a relatively common symptom that prompts medical consultation in young children ranging from 1-14% of children under 5 years globally depending on region [29] [30] [31] . As part of the investigation into the etiology of epileptic seizures, there is increasing evidence to support use of a gene panel
to disclose a genetic basis of epilepsy for childhood, late-infantile, or particularly infantile epileptic seizures. Therefore, at this stage, the clinician (Figure 1 , left) may order a gene panel directed to epilepsy and seizure disorders [32] [33] [34] [35] . Whole exome and whole genome sequencing may also be considered to uncover a previously uncharacterized genetic basis of epilepsy. Epilepsy and progressive neurodegeneration in children should raise suspicion of not only NCL, but also for gangliosidoses, mucopolysaccharidoses, mucolipidoses, Niemann-Pick type C disease, peroxisomal disorders, mitochondrial disorders, Gaucher disease type III, and leukodystrophies.
Differential diagnosis of CLN2 disease
While many of these disorders and syndromes are in fact distinguishable from the classic presentation of CLN2 disease, natural variation in clinical presentation of these disorders and syndromes often conceals an early and direct path to diagnosis of CLN2 disease.
Distinguishing between these disorders and syndromes is difficult as many lack
biochemical diagnostic tests, such as enzyme activity tests and/or biomarker tests, slowing the time to diagnosis. Fortunately, there is a biochemical test for diagnosis of CLN2 disease.
Laboratory diagnostic tests for CLN2 disease
TPP1 enzyme activity analysis
CLN2 disease is diagnosable by a biochemical test of TPP1. TPP1 enzyme is a pepstatininsensitive lysosomal serine exopeptidase with optimal in vitro activity at acidic pH [1, [36] [37] [38] . Although a tandem mass spectrometry (MS) compatible substrate was recently developed [39] , most diagnostic laboratories assess TPP1 enzyme activity using the fluorogenic substrate, Ala-Ala-Phe-7-amido-4-methylcoumarin [37, 38, 40] . Several variations on the fluorogenic methodology have been published [41] [42] [43] , each of which can differentiate affected individuals from healthy controls; however, the absolute activities differ. Therefore, it is essential that laboratories carefully establish unaffected reference ranges for their implementation of the TPP1 enzyme assay ( Figure 2 ).
Leukocytes isolated from whole blood are the recommended sample type for analysis of TPP1 enzyme activity, enabling accurate and rapid diagnostic analysis. Multiple laboratories report TPP1 enzyme activity levels measured in affected individuals to be distinct from carriers and unaffected individuals (although the absolute activities differ; Figure 2 ). However, whole blood samples are particularly sensitive to exposure to temperature extremes or to delays in shipping and receipt, potentially reducing assay reliability.
In addition to leukocytes, several other sample types may be used for analysis of TPP1 
Electron microscopy (EM) analysis
Accumulation of intracellular storage materials in neuronal and non-neuronal cells is a morphological hallmark of the NCL disorders. Historically, detection of intracellular storage materials by EM has been an important technique for the classification and diagnosis of NCL disorders [46] . The recent increase in availability of molecular testing has limited the use of EM studies in the diagnosis and differentiation of NCL disorders [23] . In addition, few laboratories now have the required expertise for the accurate interpretation of electron micrographs.
Clinical EM investigation of those suspected of having an NCL disorder typically requires collection of skin biopsies or blood samples: rectal, skeletal muscle, and conjunctival biopsies can also be used [23] . EM examination shows accumulation of storage materials, typically with curvilinear profiles in CLN2 disease. Some CLN2 disease biopsies show a mixed pattern of both curvilinear and fingerprint profiles, a pattern that may be associated with atypical CLN2 phenotypes [10, 23, 28] .
Molecular analysis of TPP1/CLN2
A diagnosis of CLN2 disease can be confirmed by identification of two pathogenic variants/mutations (associated with a TPP1 enzyme deficiency) in trans in the TPP1/CLN2 gene. The TPP1/CLN2 gene is located on chromosome 11p15 [47] , contains 13 exons, and is 6.7 kb in length. As of March 2016, 140 changes in the TPP1/CLN2
gene have been reported, of which 116 are reported to be pathogenic [13, 28, 48] .
Globally, the two most commonly reported mutations associated with CLN2 disease are are not common in all populations. Further, different mutation profiles have been reported in some locations, such as Argentina [10, 25, 26] and Canada/Newfoundland, where a founder effect mutation has been well characterized [28, 51, 52] . Consequently, global allele frequencies are not necessarily relevant for some local diagnostic purposes.
Given the broad range of mutations that have been associated with CLN2 disease [13, 28] , As with other recessive genetic disorders, molecular analysis may identify variants of unknown significance (VUS). At present, the number of reported VUS and likely nonpathogenic sequence changes in the TPP1/CLN2 gene is relatively low: of 140 reported sequence alterations, 24 alterations (17%) are not believed to be pathogenic [13, 48] .
However, it is likely that not all detected VUS have been reported. The increasing use of molecular testing in suspected cases of CLN2 disease may increase the number of VUS.
Again, if two pathogenic mutations in trans are not identified, diagnostic testing of TPP1 enzyme activity is required.
Gene panels and whole exome/genome sequencing
Relevant gene panels-such as symptom-based (epilepsy) gene panels, NCL gene panels, lysosomal disorder or inherited metabolic disorder gene panels-may speed the diagnostic process when CLN2 disease is not specifically suspected. Key strengths of gene panels include relatively rapid turnaround time, the assessment of many genetic conditions in one analysis, and the investigation of genetic conditions that are not diagnosed through enzyme activity assays as mentioned. An informal survey of US laboratories offering gene panels suggests that the TPP1/CLN2 gene is present on many gene panels, including those targeting NCL disorders, epilepsy, neurology, lysosomal storage disorders, inherited metabolic disorders, and eye disorders. The authors recommend the use of gene panels given the support they can provide clinicians in moving rapidly from clinical presentation to a laboratory diagnosis.
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Whole exome/genome sequencing (WEGS) approaches share many of the strengths of gene panels and have the advantage of examining far more of the genome, albeit with an accompanying increase in data complexity and analysis requirements. WEGS approaches may be of particular use for identification of novel diseases or if the clinical manifestation of a given mutation is outside of a gene's known disease spectrum, as was the case for the TPP1/CLN2 mutations found to cause SCAR7 disease [12] . However, not all regions will have access or support for WEGS approaches and the cost and turnaround-time relative to a gene panel is typically higher and longer.
Conclusions
In early stages, CLN2 disease is challenging to recognize, and diagnosis is often delayed until after the disease has progressed significantly. In the majority of cases, key initial symptoms are new-onset epileptic seizures in combination with a history of early language delay and/or ataxia, although alternative presentations are possible [5] . Adapted from the DEM-CHILD algorithm, http://www.dem-child.eu/index.php/ncldiagnostic-algorithm.html, and Schulz et al 2013 [14] . Highlights for "Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): expert recommendations for early detection and laboratory diagnosis" 3-5 bullets, 85 characters max (including spaces) per bullet  CLN2 disease is a rare pediatric autosomal recessive lysosomal storage disorder  Early diagnosis is important but delays are common  A group of international experts met to improve recognition and diagnosis  Initial symptoms are generally seizures, ataxia, and/or a history of language delay  Laboratory diagnosis is from deficient enzyme activity and/or molecular analysis
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